Estimating vaccine efficacy over time after a randomized study is unblinded

@article{Tsiatis2021EstimatingVE,
  title={Estimating vaccine efficacy over time after a randomized study is unblinded},
  author={Anastasios A. Tsiatis and Marie Davidian},
  journal={Biometrics},
  year={2021}
}
Abstract The COVID‐19 pandemic due to the novel coronavirus SARS CoV‐2 has inspired remarkable breakthroughs in the development of vaccines against the virus and the launch of several phase 3 vaccine trials in Summer 2020 to evaluate vaccine efficacy (VE). Trials of vaccine candidates using mRNA delivery systems developed by Pfizer‐BioNTech and Moderna have shown substantial VEs of 94–95%, leading the US Food and Drug Administration to issue Emergency Use Authorizations and subsequent… Expand

Tables from this paper

Estimation of Vaccine Efficacy for Variants that Emerge After the Placebo Group Is Vaccinated
TLDR
This work extends methods developed for estimating vaccine efficacy post placebo vaccination to allow variant specific time varying vaccine efficacy, where time is measured since vaccination, and demonstrates that useful estimation of the efficacy profile is possible for strains that emerge after vaccination of the placebo group. Expand
Identification of vaccine effects when exposure status is unknown
Results from randomized controlled trials (RCTs) help determine vaccination strategies and related public health policies. However, defining and identifying estimands that can guide policies inExpand
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated
Continued follow-up of participants in COVID-19 vaccine trials after vaccination of the placebo group permits determination of vaccine durability and allows the incorporation of a booster trial ifExpand
Assessing vaccine durability in randomized trials following placebo crossover
TLDR
It is demonstrated that the VE profile that would be observed in a placebo controlled trial is recoverable in a trial with placebo crossover and no matter when the crossover occurs, with no assumptions about the form of the efficacy profile. Expand

References

SHOWING 1-10 OF 16 REFERENCES
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
TLDR
This approach allows placebo recipients timely access to the vaccine when it would no longer be proper to maintain participants on placebo, yet still allows important insights about immunological and clinical effectiveness over time. Expand
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified. Expand
Estimability and interpretation of vaccine efficacy using frailty mixing models.
The authors consider estimability and interpretation of vaccine efficacy based on time to event data, allowing that some of the population might have a very low probability of acquiring disease, andExpand
A Frailty Mixture Model for Estimating Vaccine Efficacy
TLDR
A statistical model is derived for estimating vaccine efficacy that expresses the often unmeasured heterogeneous host response and other vaccine effects in terms of estimable parameters and incorporates the infection process into the base-line hazard rate. Expand
Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach.
We consider estimating the effect that discontinuing a beneficial treatment will have on the distribution of a time to event clinical outcome, and in particular assessing whether there is a period ofExpand
Marginal Structural Models and Causal Inference in Epidemiology
In observational studies with exposures or treatments that vary over time, standard approaches for adjustment of confounding are biased when there exist time-dependent confounders that are alsoExpand
BIAS REDUCTION USING MAHALANOBIS METRIC MATCHING
SUMMARY Monte Carlo methods are used to study the ability of nearest available Mahalanobis metric matching to make the means of matching variables more similar in matched samples than in randomExpand
Assessing vaccine durability in randomized trials following placebo crossover
TLDR
It is demonstrated that the VE profile that would be observed in a placebo controlled trial is recoverable in a trial with placebo crossover and no matter when the crossover occurs, with no assumptions about the form of the efficacy profile. Expand
andHarrington,D.P. (2005)Counting processes and survival analysis
  • 2005
Evaluating the Long-Term Efficacy of COVID-19 Vaccines
TLDR
It is shown how to estimate potentially time-varying placebo-controlled vaccine efficacy in this type of staggered vaccination of placebo recipients, and the performance of blinded and unblinded crossover designs in estimating long-term vaccine efficacy is compared. Expand
...
1
2
...